Navigation Links
WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
Date:3/2/2010

SHANGHAI, March 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Under the agreement, WuXi PharmaTech will become a provider of toxicology and other non-clinical services to JANSSEN. In addition, JANSSEN will provide training and other services, reimbursed by WuXi, to establish the GLP quality system and technical capabilities to meet the international standards at WuXi's toxicology facility in Suzhou, China.

Construction of this facility, the largest in China with 314,000 square feet of space, was completed at the end of 2008. In 2009, the company hired a management team with extensive international experience and made substantial progress in training an initial staff of technicians to perform GLP services. The facility is currently conducting non-GLP toxicology services, as well as client-sponsored GLP validation studies to demonstrate our growing capabilities. The company remains on target to begin offering GLP toxicology studies by mid-2010.

Commenting on the agreement, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "We are pleased to establish this new partnership with JANSSEN, which builds on our existing agreement to provide them with integrated pharmaceutical R&D services. We believe that China, with its high-quality scientific talent and favorable cost structure, is destined to become a major center for toxicology services over the next decade. We aim to become a leading provider of these services and to add toxicology to WuXi's broad, integrated platform of laboratory and preclinical services."

    For more information, please contact:

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.

Back to top
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
2. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
3. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... India , February 8, 2016 ... a new market research report "Ablation Technologies Market by ... (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) - ... studies the global market over the forecast period of ... $4.44 Billion by 2020, at CAGR of 10.5% from ...
(Date:2/8/2016)... Kan. , Feb. 8, 2016 /PRNewswire/ ... organization that formerly specialized in the development ... recently announced that it has divided its ... Capital. While Nueterra Capital will continue the ... services, NueHealth will operate a national system ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
Breaking Medicine Technology:
(Date:2/8/2016)... Park, KS (PRWEB) , ... February 08, 2016 , ... ... a leader in Mole removal products. , Moles are derived from a cluster of ... appear in all the wrong places and create a lifetime of embarrassment. Historically, ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
(Date:2/8/2016)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase patient awareness of the lack of ... to inform dentists and patients about the possible lack of skills and knowledge ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
(Date:2/7/2016)... AZ (PRWEB) , ... February 07, 2016 , ... ... Neck and Facial Plastics, has added Kybella® to his medical and surgical expertise. ... a newly approved FDA injectable medication used as a non-surgical alternative for reduction ...
Breaking Medicine News(10 mins):